These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1359173)

  • 1. Marked increase of CD57+CD16- cells in long-term survivors of graft-versus-host disease after allogeneic bone marrow transplantation.
    Fukuda H; Nakamura H; Tominaga N; Teshima H; Hiraoka A; Shibata H; Masaoka T
    Jpn J Clin Oncol; 1992 Aug; 22(4):238-43. PubMed ID: 1359173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked increase of CD8+S6F1+ and CD8+CD57+ cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation.
    Fukuda H; Nakamura H; Tominaga N; Teshima H; Hiraoka A; Shibata H; Masaoka T
    Bone Marrow Transplant; 1994 Feb; 13(2):181-5. PubMed ID: 7515741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased numbers of CD8+CD11+, CD8+CD11- and CD8+Leu7+ cells in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Yabe H; Yabe M; Kato S; Kimura M; Iwaki K
    Bone Marrow Transplant; 1990 May; 5(5):295-300. PubMed ID: 1693537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
    Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
    Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation.
    Sugita K; Soiffer RJ; Murray C; Schlossman SF; Ritz J; Morimoto C
    Transplantation; 1994 May; 57(10):1465-73. PubMed ID: 7910987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation.
    Rojas B; Cuhna R; Zafirakis P; Ramirez JM; Lizan-garciía M; Zhao T; Foster CS
    Exp Eye Res; 2005 Sep; 81(3):313-25. PubMed ID: 16129099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.
    D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M
    Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD.
    Lee S; Chong SY; Lee JW; Kim SC; Min YH; Hahn JS; Ko YW
    Bone Marrow Transplant; 1997 Nov; 20(10):883-8. PubMed ID: 9404931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory cells in graft-versus-host disease on the rectum: immunopathologic analysis.
    Weisdorf SA; Roy J; Snover D; Platt JL; Weisdorf DJ
    Bone Marrow Transplant; 1991 Apr; 7(4):297-301. PubMed ID: 2070136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte subset reconstitution following human allogeneic bone marrow transplantation: differences between engrafted patients and graft failure patients.
    Aotsuka N; Asai T; Oh H; Yoshida S; Itoh K; Sato T
    Bone Marrow Transplant; 1991 Nov; 8(5):345-9. PubMed ID: 1768968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.